Population Health
This adds to the more than 800 federal emergency personnel dispatched to 24 states, tribes and territories since Thanksgiving.
In the absence of those declarations, the hospital group expects the challenges of the pandemic to be "exponentially more difficult" to overcome.
Arguments center on Aduhelm's price, its questionable clinical benefit and why the agency is going against FDA approval of the drug.
This continues to outpace previous years' enrollment, including a 21% increase in plan selections through December 15, 2021.
Currently, Aduhelm, made by Biogen, is the only monoclonal antibody approved by the FDA for the treatment of Alzheimer's disease.
Hoag will become an independent entity, ending a 10-year affiliation that first showed strains during a 2020 lawsuit.
The goal is to incentivize insurers to cover these costs up-front and ensure patients don't need an order from their providers.
There are no test-out options and no exemptions, apart from medical exemptions, a move geared to protecting the health of a stretched-thin workforce.
CEO says aggressive pricing from marketplace rivals has played a role in the new projections, shifting the focus to business-wide profitability.
AMA said the new recommendations are confusing and potentially risk further spread of the virus.